Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma
Authors:
Open Access
- 7 November 2012
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 24 (4) , 1005-1010
Abstract
To select optimal candidates for extrapleural pneumonectomy (EPP), we retrospectively evaluated the usefulness of metabolic response by fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) after neoadjuvant chemotherapy to predict prognosis for patients with resectable malignant pleural mesothelioma (MPM) who underwent EPP in a multicenter study. We carried out high-resolution CT (HRCT) and FDG-PET/CT before and after neoadjuvant platinum-based chemotherapy on 50 patients with clinical T1–3 N0-2 M0 MPM who underwent EPP ± postoperative hemithoracic radiotherapy. A decrease of ≥30% in the tumor maximum standardized uptake value (SUVmax) was defined as a metabolic responder. The radiologic response using the modified RECIST or metabolic response and surgical results were analyzed. The median overall survival (OS) from diagnosis was 20.5 months. Metabolic responders significantly correlated to OS with median OS for metabolic responders not reached versus 18.7 months for non-responders. No correlation was observed between OS and radiologic response with median OS for radiologic responders and non-responders. Based on the multivariate Cox analyses, decreased SUVmax and epithelioid subtype were significantly independent factors for OS. The metabolic response after neoadjuvant chemotherapy is an independent prognostic factor for patients with resectable MPM. Patients with metabolic responder or epithelioid subtype may be good candidates for EPP.Keywords
This publication has 23 references indexed in Scilit:
- Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2009
- Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2009
- A Feasibility Study of Induction Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Postoperative Hemithoracic Radiation for Malignant Pleural MesotheliomaJapanese Journal of Clinical Oncology, 2008
- Current therapies for malignant pleural mesotheliomaEnvironmental Health and Preventive Medicine, 2008
- Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and resultsLung Cancer, 2007
- Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesotheliomaAnnals of Oncology, 2007
- Epidemiology, biologic behavior, and natural history of mesotheliomaThoracic Surgery Clinics, 2004
- Malignant mesothelioma: options for managementSurgical Clinics of North America, 2002
- The European mesothelioma epidemicBritish Journal of Cancer, 1999
- Analysis of Current Trends in United States Mesothelioma IncidenceAmerican Journal of Epidemiology, 1997